Synergistic antitumor activity of metronomic dosing of cyclophosphamide in combination with doxorubicin-containing PEGylated liposomes in a murine solid tumor model

Journal of Controlled Release

Volumn 134, Issue 3, 2009, Pages 194-200

  Ishida, Tatsuhiro ^a   Shiraga, Emi ^a   Kiwada, Hiroshi ^a  

^a Institute of Health Biosciences   (Japan)

Author keywords

Combination therapy; Cyclophosphamide; Doxorubicin; Liposomal anticancer drug; Metronomic chemotherapy; PEGylated liposome

Indexed keywords

COMBINATION THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; LIPOSOMAL ANTICANCER DRUG; METRONOMIC CHEMOTHERAPY; PEGYLATED LIPOSOME;

BLOOD VESSELS; CAPILLARITY; CELL DEATH; CHEMOTHERAPY; ENDOTHELIAL CELLS; LIPOSOMES; ONCOLOGY; PHOSPHOLIPIDS; PULSE AMPLIFIERS; SONOLUMINESCENCE;

TUMORS;

1, 2 DISTEAROYL SN GLYCERO 3 PHOSPHOETHANOLAMINE N [METHOXY(POLYETHYLENEGLYCOL) 2000]; CD31 ANTIGEN; CHOLESTEROL; CYCLOPHOSPHAMIDE; DOXORUBICIN; LIPOSOME; MACROGOL 2000; MACROGOL DERIVATIVE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL PERMEABILITY; C57BL 6 MOUSE; CANCER CHEMOTHERAPY; CANCER MODEL; CHRONOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG DIFFUSION; DRUG DOSE COMPARISON; DRUG POTENTIATION; DRUG SAFETY; ENDOTHELIUM CELL; LEUKOCYTE; LEWIS CARCINOMA; MALE; METRONOMIC CHEMOTHERAPY; MICROVASCULATURE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TOXICITY TESTING; TUMOR VASCULARIZATION; WEIGHT CHANGE;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 61349107275     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.11.019     Document Type: Article

References (34)

1. Kerbel R.S., and Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 4 (2004) 423-436
2. Gille J., Spieth K., and Kaufmann R. Metronomic low-dose chemotherapy as antiangiogenic therapeutic strategy for cancer. J. Dtsch. Dermatol. Ges. 3 (2005) 26-32
3. Laquente B., Vinals F., and Germa J.R. Metronomic chemotherapy: an antiangiogenic scheduling. Clin. Transl. Oncol. 9 (2007) 93-98
4. Munoz R., Man S., Shaked Y., Lee C.R., Wong J., Francia G., and Kerbel R.S. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res. 66 (2006) 3386-3391
5. Shaked Y., Emmenegger U., Francia G., Chen L., Lee C.R., Man S., Paraghamian A., Ben-David Y., and Kerbel R.S. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res. 65 (2005) 7045-7051
6. Browder T., Butterfield C.E., Kraling B.M., Shi B., Marshall B., O'Reilly M.S., and Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60 (2000) 1878-1886
7. Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65 (2000) 271-284
8. Jain R.K. Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. 46 (2001) 149-168
9. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., Lee K.D., Woodle M.C., Lasic D.D., Redemann C., and Martin F.J. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 11460-11464
10. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., Martin F., Huang A., and Barenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54 (1994) 987-992
11. Vaage J., Donovan D., Mayhew E., Abra R., and Huang A. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer 72 (1993) 3671-3675
12. Krown S.E., Northfelt D.W., Osoba D., and Stewart J.S. Use of liposomal anthracyclines in Kaposi's sarcoma. Semin. Oncol. 31 (2004) 36-52
13. 2. Ann. Oncol. 11 (2000) 1029-1033
14. Ishida T., Maeda R., Ichihara M., Irimura K., and Kiwada H. Accelerated clearance of PEGylated liposomes in rats after repeated injections. J. Control. Release 88 (2003) 35-42
15. Shiraga E., Barichello J.M., Ishida T., and Kiwada H. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model. Int. J. Pharm. 353 (2008) 65-73
16. Bartlett G.R. Colorimetric assay methods for free and phosphorylated glyceric acids. J. Biol. Chem. 234 (1959) 469-471
17. Bolotin E.M., Cohen R., Bar L.K., Emanuel S.N., Lasic D.D., and Barenholz Y. Ammonium sulphate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandosomes. J. Liposome. Res. 4 (1994) 455-479
18. Fukumura D. Role of microenvironment on gene expression, angiogenesis and microvascular functions in tumors. In: Meadows G.G. (Ed). Integration/Interaction of Oncologic Growth (2005), Springer Science+Business Media B.V, Dordrecht 23-36
19. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
20. Winkler F., Kozin S.V., Tong R.T., Chae S.S., Booth M.F., Garkavtsev I., Xu L., Hicklin D.J., Fukumura D., di Tomaso E., Munn L.L., and Jain R.K. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 6 (2004) 553-563
21. Fukumura D., and Jain R.K. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc. Res. 74 (2007) 72-84
22. Jain R.K., Tong R.T., and Munn L.L. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res. 67 (2007) 2729-2735
23. Hamano Y., Sugimoto H., Soubasakos M.A., Kieran M., Olsen B.R., Lawler J., Sudhakar A., and Kalluri R. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res. 64 (2004) 1570-1574
24. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J. Cell. Mol. Med. 6 (2002) 1-12
25. Tong R.T., Boucher Y., Kozin S.V., Winkler F., Hicklin D.J., and Jain R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64 (2004) 3731-3736
26. Kano M.R., Bae Y., Iwata C., Morishita Y., Yashiro M., Oka M., Fujii T., Komuro A., Kiyono K., Kaminishi M., Hirakawa K., Ouchi Y., Nishiyama N., Kataoka K., and Miyazono K. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 3460-3465
27. Ten Hagen T.L., Van Der Veen A.H., Nooijen P.T., Van Tiel S.T., Seynhaeve A.L., and Eggermont A.M. Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats. Int. J. Cancer 87 (2000) 829-837
28. Seynhaeve A.L., Hoving S., Schipper D., Vermeulen C.E., de Wiel-Ambagtsheer G., van Tiel S.T., Eggermont A.M., and Ten Hagen T.L. Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response. Cancer Res. 67 (2007) 9455-9462
29. Singal P.K., and Iliskovic N. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 339 (1998) 900-905
30. Uziely B., Jeffers S., Isacson R., Kutsch K., Wei-Tsao D., Yehoshua Z., Libson E., Muggia F.M., and Gabizon A. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J. Clin. Oncol. 13 (1995) 1777-1785
31. Goebel F.D., Goldstein D., Goos M., Jablonowski H., and Stewart J.S. Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group. Br. J. Cancer 73 (1996) 989-994
32. Northfelt D.W., Martin F.J., Working P., Volberding P.A., Russell J., Newman M., Amantea M.A., and Kaplan L.D. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J. Clin. Pharmacol. 36 (1996) 55-63
33. Koukourakis M.I., Koukouraki S., Giatromanolaki A., Archimandritis S.C., Skarlatos J., Beroukas K., Bizakis J.G., Retalis G., Karkavitsas N., and Helidonis E.S. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J. Clin. Oncol. 17 (1999) 3512-3521
34. Quesada A.J., Nelius T., Yap R., Zaichuk T.A., Alfranca A., Filleur S., Volpert O.V., and Redondo J.M. In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment. Cell. Death Differ. 12 (2005) 649-658